Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).
RemeGen Co., Ltd. has released its unaudited 2025 third quarterly report, prepared according to Chinese accounting principles and the STAR Market requirements of the Shanghai Stock Exchange. The report, which has been reviewed by the audit committee but not by independent auditors, emphasizes the company’s commitment to transparency and accuracy in its financial disclosures, advising shareholders and potential investors to exercise caution when dealing with its securities.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$88.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, primarily operating in the biotechnology industry. The company is listed on the Stock Exchange of Hong Kong and focuses on developing innovative biopharmaceutical products.
Average Trading Volume: 7,627,887
Technical Sentiment Signal: Buy
Current Market Cap: HK$53.26B
For detailed information about 9995 stock, go to TipRanks’ Stock Analysis page.